iBio (IBIO) FY2026 10-K Risk Factors: 18 New, 11 Dropped

What the changes say

IBIO-600 is now in a Phase 1 Australian trial, adding country-specific regulatory, enrollment, CRO and FDA-data-acceptance exposure.
The pipeline shifted away from immune-oncology toward obesity, cardiometabolic and cardiopulmonary diseases, concentrating development risk.
Fiscal 2026 net loss rose to $33.0 million and accumulated deficit reached $365.3 million.
New disclosures emphasize data security, AI platform reliability, clinical-trial execution and late-stage failure of candidates.

What changed since the prior 10-K

New

NewRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
o Final data for our clinical trials may materially differ from preliminary results that we announce or publish
Preliminary clinical results, patient enrollment, IBIO-600 development, Australian studies, side effects and product liability could delay or derail programs.
NewRisks Related to iBio’s Operations
o Any failure to maintain data security could result in litigation and enforcement actions
Cybersecurity, privacy-law violations, AI/ML problems, economic conditions and climate regulation could trigger costs, enforcement or operational harm.
NewRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
result, we may fail to address or develop product candidates based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success
Research programs may fail to produce candidates, causing iBio to miss scientifically stronger or more commercially promising opportunities.
NewRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
qualified subjects, or because the stringency of requirements for enrollment limits the number of people who are eligible to participate in the clinical trial
Safety events, regulator or review-board intervention, restrictive approvals and unwanted effects could suspend trials or make products uneconomic.
NewRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
accompanying label may limit the approved use in such a restrictive manner that it is not possible to obtain commercial viability for such product
Changing approval rules, deficient applications, insufficient data or differing interpretations could delay, restrict or prevent marketing approval.
NewRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
The results or success of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of future results or replicated in later preclinical studies or clinical trials of our product candidates in the same indications or other indications
Positive preclinical or early clinical findings may not predict later safety, efficacy or performance in different patient populations.
NewRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
Delays or difficulty in the enrollment of patients in any or all of our clinical trials could increase our development costs and delay completion of our clinical trials and associated regulatory submissions
Enrollment may be slowed by eligibility rules, limited patients or sites, travel barriers, recruitment challenges, consent issues and dropouts.
NewRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
Our Phase 1 clinical trial of IBIO-600 is subject to significant risks that could delay or prevent further development of this product candidate
The Phase 1 IBIO-600 trial could face adverse events, regulatory action, weak later efficacy, FDA rejection of Australian data or CRO failures.
NewRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
Conducting clinical trials in Australia exposes us to additional regulatory, operational and legal risks that could delay development of our product candidates and increase our costs
Australian laws, authorities, ethics approvals, staffing, enrollment and cross-border trial management may delay development or increase costs.
NewRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
events caused by any product candidate administered in combination with our product candidates could cause similar interruptions and delays, even though not caused by our product candidates
Serious or unexpected side effects could prompt withdrawal, warnings, additional trials, lawsuits, discontinuation or reputational damage after approval.
NewRisks Related to Dependence on Third Parties
experience, interruptions, delays and outages in service and availability from time to time due to a variety of factors, including infrastructure changes, human or software errors, website hosting disruptions and capacity constraints
AI platform outages, unreliable performance, controversial data practices, regulation or stronger competitors could reduce customer use and competitiveness.
NewRisks Related to Dependence on Third Parties
Our failure or any failure by these third parties to comply with these regulations would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws
CRO and trial-site staffing shortages, competing engagements or regulatory violations could impair clinical studies and delay approvals.
NewRisks Related to Dependence on Third Parties
Our use of hazardous and biological materials could result in us being liable for damages
NewRisks Related to iBio’s Operations
operations, quality control, technical support and other administrative functions. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls
NewRisks Related to iBio’s Operations
Failure to comply with health care privacy and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business
NewRisks Related to iBio’s Operations
The use of AI and ML technologies in our business operations and product offerings may expose us to risks that could harm our competitive position and have a material adverse effect on our business and results of operations
NewRisks Related to iBio’s Operations
candidates more efficiently than existing industry tools and have a material adverse effect on our business, financial condition, results of operations or prospects
NewRisks Related to Our Common Stock
manufacturing contracts, facility build-out and technology transfer contracts, licensing and other arrangements. Sources of funds may not be available or, if available, may not be available on terms satisfactory to us

Dropped

DroppedRisks Related to Our Business, Financial Position and Capital Requirements
o The actual amount of funds we will need to operate is subject to many risk factors, some of which are beyond our control
Operating-fund requirements and limits on raising capital while public float remains below $75 million.
DroppedRisks Related to Dependence on Third Parties
o Our most advanced product candidates depend on intellectual property licensed from third parties and termination of any of these or future licenses could result in the loss of significant rights, which could adversely affect our business, results of operations and financial condition
DroppedRisks Related to Dependence on Third Parties
o If we are unable to establish new collaborations and maintain both new and existing collaborations, or if these collaborations are not successful, our business could be adversely affected
Licensed intellectual property, third-party databases, and contract-manufacturer supply interruptions.
DroppedRisks Related to iBio’s Operations
o We rely extensively on our information technology systems and are vulnerable to damage and interruption, including cybersecurity and data leakage risks
Collaborations, third-party study performance, supplies, insurance coverage and litigation exposure.
DroppedRisks Related to Our Business, Financial Position and Capital Requirements
of the significant uncertainty regarding our future plans, we are not able to accurately predict the impact of a potential change in our business strategy and future funding requirements
Information-system failures, cybersecurity and data leakage, economic or geopolitical change, and climate regulation.
DroppedRisks Related to Our Business, Financial Position and Capital Requirements
clinical development without securing collaborator or licensee funding, our research and development expenses could increase substantially
DroppedRisks Related to Our Business, Financial Position and Capital Requirements
Our ability to raise additional capital, including through sales of shares of common stock under the ATM Program, may be limited if the public float of our common stock continues to be less than $75.0 million
DroppedRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
We are currently in preclinical development of multiple product candidates as potential treatments across multiple therapeutic areas. It is possible that we may never be able to develop a marketable product candidate
Uncertain business strategy and funding needs, with products potentially generating no revenue for years.
DroppedRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
extensive, lengthy, expensive, and inherently uncertain process, and the FDA may delay, limit or deny approval of its product for many reasons
DroppedRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
We may conduct our initial clinical studies for IBIO-610 and our other product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such studies, in which case our development plans will be delayed, which could materially harm our business
DroppedRisks Related to iBio’s Operations
In the past we have identified and remediated material weaknesses in our internal controls, and we cannot provide assurances additional material weaknesses will not occur in the future
Need for external funding or collaborators to continue clinical development and finance rising research costs.

Reworded

90% rewrittenRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
All of our existing product candidates are in early stages of development and will require extensive additional clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment before they could provide us with any revenue
The pipeline is now described as IBIO-600 in Phase 1 plus preclinical candidates, after abandoning immune-oncology and impairing IBIO-101.
75% rewrittenRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
Neither we nor our clients, collaborators or potential licensees will be able to commercialize product candidates based on our technologies and services if preclinical studies do not produce successful results or clinical trials do not demonstrate safety and efficacy in humans
The supplied prior- and current-year excerpts are substantively identical; no specific change is visible.
74% rewrittenRisks Related to Dependence on Third Parties
Our AI/ML platform leverages internal data as well as data from third parties. Defects in, or loss of access to, our databases or those of third parties may impair our ability to discover additional targets and develop our product candidates
The current text drops the ShieldTx patent-application description and adds that parts of the AI/ML program are protected by trade secrets.
72% rewrittenRisks Related to iBio’s Operations
We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy
The supplied current-year excerpt is truncated and otherwise matches the prior-year wording shown; no specific change is visible.
64% rewrittenRisks Related to Dependence on Third Parties
If we encounter any of these problems or are otherwise delayed, or if the cost of manufacturing is not economically feasible or we cannot find another third-party manufacturer, we may not be able to produce our clinical product candidate in a sufficient quantity to meet future demand
The supplied prior- and current-year excerpts are substantively identical; no specific change is visible.
59% rewrittenRisks Related to Our Business, Financial Position and Capital Requirements
In addition, as we expand our business, we will need to retain additional employees with the necessary skills including employees for our continued expansion of drug discovery capabilities in San Diego, California
The supplied excerpts repeat the same loss, cash-flow and profitability discussion; the apparent heading change is not supported by the displayed text.
54% rewrittenRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
o Clinical trials are very expensive, time-consuming, and difficult to design and implement
The current version adds that early clinical results may not predict final results, while dropping foreign-study, side-effect and product-liability examples.
50% rewrittenRisks Related to Our Business, Financial Position and Capital Requirements
We have incurred significant losses since our inception. We expect to incur losses during our next fiscal year, we do not anticipate generating significant revenue for several years and may never achieve or maintain profitability
Fiscal 2026 net loss increased to $33.0 million from $18.4 million, accumulated deficit reached $365.3 million, and focus shifted to precision antibodies for obesity and cardiometabolic and cardiopulmonary diseases.
47% rewrittenRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
Our product candidates may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical products, which may delay or preclude its development or regulatory approval or limit its use if ever approved
46% rewrittenRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
We currently have a limited operating history developing precision antibodies, no products approved for commercial sale, have no significant source of revenue and may never generate significant revenue
38% rewrittenRisks Related to Dependence on Third Parties
If third parties on whom we or our licensees will rely for the conduct of preclinical studies and clinical trials do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business may suffer
34% rewrittenRisks Related to Our Business, Financial Position and Capital Requirements
We have a limited operating history developing precision antibody therapeutics, which may limit the ability of investors to make an informed investment decision
Was: We have a limited operating history developing vaccines and therapeutics, which may limit the ability of investors to make an informed investment decision
25% rewrittenRisks Related to the Development and Commercialization of Our Technologies and Product Candidates
Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
22% rewrittenRisks Related to Our Common Stock
Our failure to meet the listing requirements of Nasdaq could result in a delisting of our common stock. Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if our common stock is delisted
Was: Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock. Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if our common stock is delisted

All 70 risk factors

Headings as the filing states them, in filing order.

Risks Related to the Development and Commercialization of Our Technologies and Product Candidates

01o Clinical trials are very expensive, time-consuming, and difficult to design and implement54% rewritten
02o Final data for our clinical trials may materially differ from preliminary results that we announce or publishNew
09We currently have a limited operating history developing precision antibodies, no products approved for commercial sale, have no significant source of revenue and may never generate significant revenue46% rewritten
10All of our existing product candidates are in early stages of development and will require extensive additional clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment before they could provide us with any revenue90% rewritten
11result, we may fail to address or develop product candidates based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of successNew
12We may expend our limited resources to pursue a particular technology or product candidate and fail to capitalize on technologies or product candidates that may be more profitable or for which there is a greater likelihood of success
13If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements on terms less favorable to us than possible
14If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially harm our business
15Clinical trials are very expensive, time-consuming, and difficult to design and implement
16Neither we nor our clients, collaborators or potential licensees will be able to commercialize product candidates based on our technologies and services if preclinical studies do not produce successful results or clinical trials do not demonstrate safety and efficacy in humans75% rewritten
17qualified subjects, or because the stringency of requirements for enrollment limits the number of people who are eligible to participate in the clinical trialNew
18accompanying label may limit the approved use in such a restrictive manner that it is not possible to obtain commercial viability for such productNew
19If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired
20Alternative technologies may supersede our technologies or make them noncompetitive, which would harm our ability to generate future revenue
21The results or success of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of future results or replicated in later preclinical studies or clinical trials of our product candidates in the same indications or other indicationsNew
22Delays or difficulty in the enrollment of patients in any or all of our clinical trials could increase our development costs and delay completion of our clinical trials and associated regulatory submissionsNew
23Our Phase 1 clinical trial of IBIO-600 is subject to significant risks that could delay or prevent further development of this product candidateNew
24Conducting clinical trials in Australia exposes us to additional regulatory, operational and legal risks that could delay development of our product candidates and increase our costsNew
25Our product candidates may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical products, which may delay or preclude its development or regulatory approval or limit its use if ever approved47% rewritten
26events caused by any product candidate administered in combination with our product candidates could cause similar interruptions and delays, even though not caused by our product candidatesNew
27Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop25% rewritten

Risks Related to iBio’s Operations

03o Any failure to maintain data security could result in litigation and enforcement actionsNew
48The loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business
49A failure by us to hire and retain an appropriately skilled and adequate workforce could adversely impact the ability to operate our R&D facility efficiently
50Use of our laboratory space in San Diego is critical to our success. A natural disaster or other disruptions at our laboratory would adversely affect our business, financial condition, and results of operations
51We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy72% rewritten
52operations, quality control, technical support and other administrative functions. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controlsNew
53If we acquire companies, products or technologies, we may face integration risks and costs associated with those acquisitions that could negatively impact our business, results from operations and financial condition
54Our business and operations would suffer in the event of computer system failures
55We rely extensively on our information technology systems and are vulnerable to damage and interruption, including cybersecurity and data leakage risks
56Failure to comply with health care privacy and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and businessNew
57The use of AI and ML technologies in our business operations and product offerings may expose us to risks that could harm our competitive position and have a material adverse effect on our business and results of operationsNew
58candidates more efficiently than existing industry tools and have a material adverse effect on our business, financial condition, results of operations or prospectsNew
59Changes in general economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may adversely impact our business and operating results
60Global climate change and related regulations could negatively affect our business

Risks Related to Our Business, Financial Position and Capital Requirements

04We have a limited operating history developing precision antibody therapeutics, which may limit the ability of investors to make an informed investment decision34% rewritten
05We have incurred significant losses since our inception. We expect to incur losses during our next fiscal year, we do not anticipate generating significant revenue for several years and may never achieve or maintain profitability50% rewritten
06We anticipate that our expenses will increase in the future
07In addition, as we expand our business, we will need to retain additional employees with the necessary skills including employees for our continued expansion of drug discovery capabilities in San Diego, California59% rewritten
08The actual amount of funds we will need to operate is subject to many risk factors, some of which are beyond our control

Risks Related to Dependence on Third Parties

28Our most advanced product candidates depend on intellectual property licensed from third parties and termination of any of these or future licenses could result in the loss of significant rights, which could adversely affect our business, results of operations and financial condition
29Our AI/ML platform leverages internal data as well as data from third parties. Defects in, or loss of access to, our databases or those of third parties may impair our ability to discover additional targets and develop our product candidates74% rewritten
30experience, interruptions, delays and outages in service and availability from time to time due to a variety of factors, including infrastructure changes, human or software errors, website hosting disruptions and capacity constraintsNew
31If we encounter any of these problems or are otherwise delayed, or if the cost of manufacturing is not economically feasible or we cannot find another third-party manufacturer, we may not be able to produce our clinical product candidate in a sufficient quantity to meet future demand64% rewritten
32If we are unable to establish new collaborations and maintain both new and existing collaborations, or if these collaborations are not successful, our business could be adversely affected
33If third parties on whom we or our licensees will rely for the conduct of preclinical studies and clinical trials do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business may suffer38% rewritten
34Our failure or any failure by these third parties to comply with these regulations would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security lawsNew
35We rely on third parties to supply the raw materials needed to operate our research and development activities and do not have any long-term commitments from such suppliers
36Our use of hazardous and biological materials could result in us being liable for damagesNew
37Any claims beyond our insurance coverage limits, or that are otherwise not covered by our insurance, may result in substantial costs and a reduction in our available capital resources
38We may be subject to various litigation claims and legal proceedings

Risks Related to Intellectual Property

39If we are unable to protect the confidentiality of our partners’ or collaborators’ proprietary information, we may be subject to claims
40We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and ultimately unsuccessful
41Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
42If we are unable to protect our trade secrets, our business and competitive position would be harmed
43We may be subject to claims challenging the inventorship of our patent filings and other intellectual property
44Intellectual property rights do not necessarily address all potential threats to our competitive advantage
45We may not be able to protect our intellectual property rights throughout the world
46If we should fail to comply with various patent laws our patent protection could be reduced or eliminated
47Changes in patent law, including recent patent reform legislation, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents

Risks Related to Our Common Stock

61manufacturing contracts, facility build-out and technology transfer contracts, licensing and other arrangements. Sources of funds may not be available or, if available, may not be available on terms satisfactory to usNew
62Our failure to meet the listing requirements of Nasdaq could result in a delisting of our common stock. Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if our common stock is delisted22% rewritten
63Provisions in our certificate of incorporation, bylaws and under Delaware law could discourage a takeover that stockholders may consider favorable
64Our Second Amended and Restated Bylaws provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees
65The issuance of preferred stock could adversely affect the rights of the holders of shares of our common stock
66We do not intend to pay dividends in the foreseeable future
67Holders of our warrants issued in our offerings have no rights as common stockholders until they exercise their warrants and acquire our common stock
68The market price of our common stock has been and may continue to be volatile and adversely affected by various factors
69Reports published by securities or industry analysts, including projections in those reports that exceed our actual results, could adversely affect our common stock price and trading volume
70We are a “smaller reporting company”, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors

Other iBio 10-Ks

FY2025 10-K risk factors
63 risks18 new10 dropped10 reworded
iBio faces severe going concern risks with an accumulated deficit of $332.2 million as of June 30, 2025. Raising capital is constrained because its public float dropped to approximately $20.0 million, well below the $75.0 million threshold. All product candidates remain in preclinical development, focusing primarily on cardiometabolic and obesity fields.
Filed Sep 05, 2025
FY2024 10-K risk factors
55 risks
The risk profile is dominated by severe liquidity concerns, ongoing operating losses, and a looming going concern doubt. The company faces high dependence on third-party manufacturers, unproven artificial intelligence drug discovery technologies, and early-stage preclinical assets. Operations are threatened by the need for additional capital raising, which risks significant dilution for existing stockholders.
Filed Sep 20, 2024

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.